

## REAL WORLD TESTING PLAN

### GENERAL INFORMATION

Plan Report ID Number:

Developer Name: Health Information Management Systems, LLC

Product Name(s): Axiom

Version Number(s): 7

Certified Health IT Product List (CHPL) ID(s): 15.04.04.1590.Axio.02.01.1.201229

Developer Real World Page URL: <https://hmsfirst.com/Axiom-Real-World-Testing-Plan-2024>

## **JUSTIFICATION FOR REAL WORLD TESTING APPROACH**

At this time, the Axiom product serves customers in the integrated health sector and as such the Real World Testing plan will be applied to this care setting. Several certification criteria will be tested simultaneously. This plan is similar to last year's test plan with modifications in adding 170.315(g)(10) and removing 170.315(g)(8).

This test plan will include 170.315 (b)(1): Transitions of Care, 170.315 (c)(1): Clinical Quality Measures (CQMS) - Record and Export, 170.315 (f)(5): Transmission to Public Health Agencies - Electronic Case Reporting, 170.315 (g)(7): Application Access - Patient Selection, 170.315 (g)(9): Application Access - All Data Request, 170.315 (g)(10): Standardized API for patient and population services.

**STANDARDS UPDATES (INCLUDING STANDARDS VERSION ADVANCEMENT PROCESS (SVAP) AND UNITED STATES CORE DATA FOR INTEROPERABILITY (USCDI))**

We will not make any version updates on approved standards through SVAP

Standard (and version)	Not applicable
Date of ONC-ACB notification (SVAP or USCDI)	Not applicable
Date of customer notification (SVAP only)	Not applicable
USCDI-updated criteria	Not applicable

**MEASURES USED IN OVERALL APPROACH**

**Measure 1:**

**Measure Description:** Track C-CDA generation and successful transmission of such data.

**Associated Certification Criteria:** 170.315 (b)(1): Transitions of Care

**Justification:** This measurement tracks C-CDA transmission using Direct Messaging. Surescripts Clinical Direct Messaging will be used as relied upon software to achieve this outcome.

**Care Settings:** One Integrated Healthcare client will be used to test this measurement and demonstrate its capabilities.

**Expected Outcomes:** 100%, success rate, of the C-CDA data files were sent using Direct Messaging and correctly validated during the reporting period. Surescripts Clinical Direct Messaging will be used as relied upon software to achieve this outcome.

**Measure 2:**

**Measure Description:** Ability to track electronic Clinical Quality Measure and exporting such data to reporting agencies.

**Associated Certification Criteria:** 170.315 (c)(1): Clinical Quality Measures - Record and Export

**Justification:** Provide a count of Clinical Quality Measures that will be transmitted which complies with the reporting requirements.

**Care Settings:** One Integrated Healthcare client will be used to test this measurement and demonstrate its capabilities to record and export clinical quality measures.

**Expected Outcomes:** Over the report period, it is expected that 90% of the files generated will be successfully transmitted to reporting agencies.

**Measure 3:**

**Measure Description:** Determine cases for transmitting electronic patient information to public health agencies.

**Associated Certification Criteria:** 170.315 (f)(5): Transmission to Public Health Agencies - Electronic Case Reporting

**Justification:** Conduct real world interoperability regarding data transmission to public health agencies.

**Care Settings:** One Integrated Healthcare client will be used to test this measurement and demonstrate its capabilities.

**Expected Outcomes:** Over the reporting period, it is expected that a success rate of 100% of the immunization records will be transmitted successfully to public health agency.

**Measure 4:**

**Measure Description:** Ability to receive patient requests using an API and returning unique data specific to the patient.

**Associated Certification Criteria:** 170.315 (g)(7): Application Access - Patient Selection

**Justification:** Currently, none of the customers are using this criterion. Discussion with the customer regarding the use of this functionality, the benefits, and barriers to utilizing this functionality will be discussed.

**Care Settings:** One Integrated Healthcare client will be used to test this measurement and demonstrate its capabilities.

**Expected Outcomes:** Identify barriers to utilizing this functionality and help evaluate its use in a real-world setting. Once identified and the issues are addressed, we expect to have 75% success rate of receiving patient requests and returning data specific to patients.

**Measure 5:**

**Measure Description:** The ability of the API to provide patient data based on specific criteria like date range or criteria.

**Associated Certification Criteria:** 170.315 (g)(9): Application Access - All Data Request

**Justification:** Currently, none of the customers are using this criterion. Discussion with the customer regarding the use of this functionality, the benefits, and barriers to utilizing this functionality will be discussed.

**Care Settings:** One Integrated Healthcare client will be used to test this measurement and demonstrate its capabilities.

**Expected Outcomes:** Identify barriers to utilizing this functionality and help evaluate its use in a real-world setting. Once identified and the issues are addressed, we expect to have 90% success rate of providing response based on patient specific criteria.



**Measure 6:**

**Measure Description:** The ability of the API to provide Standardized API for patient and population services.

**Associated Certification Criteria:** 170.315 (g)(10): Standardized API for patient and population services.

**Justification:** Currently, none of the customers are using this criterion. Discussion with the customer regarding the use of this functionality, the benefits, and barriers to utilizing this functionality will be discussed.

**Care Settings:** One Integrated Healthcare client will be used to test this measurement and demonstrate its capabilities.

**Expected Outcomes:** Identify barriers to utilizing this functionality and help evaluate its use in a real-world setting. Once identified and the issues are addressed, we expect to have 70% success rate of providing response based on patient specific criteria.

**SCHEDULE OF KEY MILESTONES**

Key Milestones	Date/Timeframe
Release of documentation for the Real-World Testing to be provided to authorized representatives and providers. This includes surveys, specific instructions on what to look for, how to record issues encountered, and Customer Agreements.	January 2024
Begin collection of information as laid out by the plan for the period.	February 2024
Meet with previously identified providers and authorized representatives to ensure that Real World Testing protocols are effective.	March 2024
Follow-up with providers and authorized representatives on a regular basis to understand any issues arising with the data collection.	Quarterly, 2024
Data collection and review.	Quarterly, 2024
End of Real-World Testing period/final collection of all data for analysis.	January 1, 2025
Analysis and report creation.	January 15, 205
Submit Real World Testing report to ACB (per their instructions)	February 1, 2025

**ATTESTATION**

This Real World Testing plan is complete with all required elements, including measures that address all certification criteria and care settings. All information in this plan is up to date and fully addresses the health IT developer's Real World Testing requirements.

Authorized Representative Name:  
Tania Capin

Authorized Representative Email:  
certification@hmsfirst.com

Authorized Representative Phone: (520) 278-5037

Authorized Representative Signature:

A handwritten signature in black ink that reads "Tania Capin". The signature is written in a cursive, flowing style.

Date: 11/1/2023